Targeting ACE2 and TMPRSS2 not only has important prospects as a therapeutic strategy against COVID‐19 and other coronaviruses, especially for cancer patients who may change the expression of these proteins due to malignant tumors or treatments. Here, ACE2 is linked to COVID-19.